Home › Graves Ophthalmopathy
Graves Ophthalmopathy clinical trials recruiting in the U.S.
6 studies for Graves Ophthalmopathy are recruiting participants at sites across the United States.
Recently updated studies
A Study of VV-14305 for the Treatment of Thyroid Eye Disease
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Aug 27, 2026 · NCT07404111Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07753603An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
RecruitingPhase 2
Ages 18 to 99 · All sexes · Updated Jul 23, 2026 · NCT07438405Bimatoprost as a Treatment for Graves' Orbitopathy
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT03708627Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Feb 25, 2025 · NCT06112340The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Feb 23, 2024 · NCT06275373From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.